Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome

Status Completed

Clinical Trial Summary

Immature platelet fraction is a non-invasive test of real time thrombopoiesis. High IPF% has been suggested as an indicator of thrombocytopenia due to rapid platelet consumption. IPF% is able to discriminate between patients with TTP/HUS or SPE/HELLP

Clinical Trial Description

Thrombotic microangiopathy (TMA) syndromes are extraordinarily diverse. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are the two most well known, and are considered to be the most serious. TTP-HUS occurs more commonly in women and among women is commonly associated with pregnancy.

Nevertheless, there are other pregnancy conditions that may manifest with TMA, including preeclampsia, eclampsia, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), in addition to acute fatty liver of pregnancy, antiphospholipid syndrome, and systemic lupus erythematosis.

Assessment of immature platelets was introduced as a non-invasive test of real time thrombopoiesis. They are newly released in the circulation with a larger size & greater RNA content than mature platelets, and can be measured by automated haematology analyzer equipped with reticulocyte detection channel and described as immature platelet fraction (%-IPF) and immature platelet count (A-IPC).

A high %-IPF has been suggested as an indicator of thrombocytopenia due to rapid platelet consumption, while a low %-IPF is characteristic of bone marrow suppression states. %-IPF/A-IPF has the competency to be performed routinely and, therefore, can provide therapeutic and diagnostic feedback in the life threatening conditions.

The present study aimed to show the utility of estimating %-IPF and A-IPC using a reticulocyte detection channel CBC autoanalyzer as a simple reproducible blood analysis to be employed in the differential diagnosis of pregnancy-associated thrombotic microangiopathic conditions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03232359
Study type	Observational [Patient Registry]
Source	Ain Shams Maternity Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2015
Completion date	June 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Recruiting	`NCT02247297` - Pancreatic Stone Protein (PSP) in Pregnant Women
Terminated	`NCT04725812` - Complement Regulation to Undo Systemic Harm in Preeclampsia	Phase 2
Recruiting	`NCT02020174` - The Preeclampsia Registry
Recruiting	`NCT06377878` - The Preeclampsia Registry
Recruiting	`NCT02920593` - A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy	Phase 4
Recruiting	`NCT01138839` - Dexamethasone Efficacy in HELLP I Syndrome	Phase 3
Recruiting	`NCT05500989` - PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
Completed	`NCT04216706` - Early Vascular Adjustments to Prevent Preeclampsia
Recruiting	`NCT03834285` - Liver Disease in Pregnancy
Completed	`NCT00000534` - Calcium for Pre-Eclampsia Prevention (CPEP)	Phase 3
Recruiting	`NCT02807324` - Women Specific Cardiac Recovery After Preeclampsia
Completed	`NCT01736826` - Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Terminated	`NCT00711841` - Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome	Phase 4
Completed	`NCT00097110` - RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil	Phase 3
Completed	`NCT03715647` - Correlation of Survival in Puerperae by Electrical Impedance Tomography
Completed	`NCT03455387` - Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
Completed	`NCT03246542` - Promising Bimarker Prediction of Outcome of HELLP Syndrome.	N/A
Completed	`NCT02754778` - Influence of Conditional Workout Postpartum on Arterial Stiffness Among Women With Status After Preeclampsia, Superimposed Preeclampsia or HELLP-syndrome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms